A comparison of overall survival with brexucabtagene autoleucel (Brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi)
Hess, G. Dreyling, M. Oberic, L. Gine, E. Zinzani, P. L. Linton, Kim M Vilmar, A. Jerkeman, M. Chen, J. M. H. Ohler, A.
Hess, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Citations
Altmetric:
Abstract
Authors
Hess, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Jimenez-Ubieto, A.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Castaigne, G.
Salles, G.
Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Jimenez-Ubieto, A.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Castaigne, G.
Salles, G.
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton KM, et al. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). Blood. 2022 Nov;140:10296-9. PubMed PMID: WOS:000893230303139.